Analysis

​​​​​​​Allergan's $750M Deal Among Pharma's Top Antitrust Payouts

Law360 (October 29, 2019, 9:06 PM EDT) -- A $750 million settlement this week by Allergan to avert an antitrust trial involving Alzheimer's drug Namenda is among the most eye-popping sums ever shelled out by a drugmaker for allegedly thwarting generic competition.

Allergan announced the nine-figure payout just as trial proceedings were set to start Monday in New York federal court. The accord will resolve allegations from wholesalers that have accused Allergan's Forest Laboratories unit of unlawful monopolization via "pay-for-delay" arrangements and "product hopping" tactics that protected Namenda profits long after generic rivals should have developed robust sales.

Those types of allegations are among the most common driving forces...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!